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Abstract
Whereas early Alzheimer disease (AD) neuropathology and mild cognitive impairment are relatively common in aging,
accurate prediction of patients that will progress to dementia requires new biomarkers. Recently, substantial work has
focused on phospho-tau/MAPT (p-MAPT) neuropathology since its regional propagation correlates with the degree of
cognitive impairment in AD. Recent diffusion tensor imaging studies in AD suggest that increased diffusion in the fornix
secondary to p-MAPT-related axonal injury could serve as a predictive biomarker of the risk of disease progression.
However, our knowledge of p-MAPT neuropathology in the fornix is limited. To address this gap in knowledge, we
examined p-MAPT neuropathology in the fornix and basal forebrain nuclei via AT8 immunohistochemistry in 39 brain
autopsies spanning the spectrum of AD neuropathologic changes. We found that the fornix and its precommissural
efferent target nuclei (septum and nucleus accumbens) demonstrated neuronal and thread-like p-MAPT neuropathology
only in National Institute on Aging/Alzheimer Association (NIA/AA) stages B2 and B3 of neurofibrillary degeneration,
consistent with involvement after (and propagation from) the hippocampal formation. Interestingly, although tau
astrogliopathy was frequently observed in the mammillary bodies in stage B2, neuronal tauopathy was not observed in
the postcommissural targets (mammillary bodies and anterior thalamic nucleus) until stage B3. Tauopathy in the nucleus
basalis of Meynert was strongly correlated with p-MAPT-positive axons in the fornix, suggesting that projections to the
hippocampus also likely contribute to fornix tauopathy. Our cross-sectional autopsy findings indicate that the fornix is
involved by p-MAPT neuropathology secondary to hippocampal involvement by AD neuropathology. Furthermore, our
findings are compatible with the goal of in vivo detection of p-MAPT-related axonal pathology in the fornix in AD as a
possible biomarker of p-MAPT progression from the hippocampal formation and underscore a need for additional
clinical-radiologic-pathologic correlation studies.
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Introduction
Alzheimer disease (AD) is a common age-related neuro-
degenerative disease that is typically characterized by an
early stage of amnestic mild cognitive impairment which
can progress to multi-domain cognitive deterioration and
dementia. Recent decades of clinical studies and bench
research have rendered critical insights into the pathologic
mechanisms of the disease, but efforts to translate mech-
anistic insights into effective disease treatments have yet
to achieve therapeutic goals. One potential explanation
for the inefficacy of new experimental treatments is
that they have been studied in patients with advanced
disease when a window for functional recovery has
closed. This possibility mandates a better understand-
ing of early AD neuropathology as well as the discovery
of novel biomarkers that herald disease onset and that ac-
curately identify the risk for progression from mild cogni-
tive impairment (MCI) to dementia in sporadic AD.
AD is defined neuropathologically by dual proteino-
pathies: 1. extracellular plaques comprised of amyloid-
beta (Aβ) and 2. intracellular neurofibrillary tangles
* Correspondence: ploweyed@stanford.edu
Department of Pathology, Stanford University School of Medicine, Edwards
Building, Room R-241, 300 Pasteur Drive, Stanford, CA 94305, USA
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Plowey and Ziskin Acta Neuropathologica Communications  (2016) 4:114 
DOI 10.1186/s40478-016-0388-2
comprised of phosphorylated microtubule associated
protein tau (p-MAPT). Evidence suggests that both
neuritic plaques (a subset of extracellular Aβ plaques
demonstrating argyrophillic, p-MAPT-immunoreactive
dystrophic neurites) and neurofibrillary tangles con-
tribute to cognitive impairment [15–17, 21], however
their relative contributions and interactions are not
completely understood. The National Institute on
Aging/Alzheimer Association (NIA/AA) AD staging
system [12], which is based in part on the Braak sta-
ging system of neurofibrillary degeneration [2–4],
delineates the typical progression of cerebral neurofib-
rillary degeneration in AD beginning in the transen-
torhinal and entorhinal cortices (B1), progression into
the hippocampal formation (B2) and then culminating
in involvement of the association neocortices followed
by the primary neocortices (B3). This stereotypical
progression suggests a possible role for axons and
synapses in the p-MAPT neuropathology propagation.
The importance of p-MAPT neuropathology is under-
scored by the strong correlation between neocortical
neurofibrillary degeneration and cognitive impairment
in AD demonstrated in numerous clinicopathologic
correlation studies (reviewed in Nelson et al. 2012
[16]). Whereas entorhinal NFTs are a near universal
finding in cognitively intact elderly adults, amnestic
MCI is associated with limbic stage neurofibrillary
degeneration and multi-domain cognitive impairment
in AD is highly correlated with isocortical neurofibril-
lary tangles [16]. Although there is compelling evidence
that a small but significant proportion of AD presents
with atypical clinical features and progression of neuro-
fibrillary degeneration, especially in young patients
[13], the typical progression of tau neuropathology sug-
gests that imaging modalities to detect tau spread in
vivo may render novel AD biomarkers. Furthermore,
diffusion tensor imaging (DTI) has recently received
attention as a modality to detect p-MAPT-related
axonal injury in the fornix in AD [1, 18]. These
advances have a great potential to reveal novel insights
into biomarkers that can predict patients at risk of pro-
gression from MCI to dementia in AD.
Our search of the literature suggested that the
propagation of p-MAPT neuropathology from the
hippocampus in AD is incompletely understood. To
our knowledge, p-MAPT neuropathology in the fornix
in the spectrum of AD neuropathologic changes has
not been reported. The fornix is a major tract of
efferent fibers from the hippocampal formation
(reviewed in Duvernoy et al. [9]). Efferent fibers of
the postcommissural fornix innervate the mammillary
body and anterior thalamic nucleus in the regulation
of memory. Efferent fibers of the precommissural for-
nix innervate the septum in the regulation of memory
and the nucleus accumbens in the control of move-
ment. The fornix also carries afferent fibers into the
hippocampal formation, notably cholinergic fibers
from the septum and nucleus basalis of Meynert in
the control of memory. Considering its important role
in hippocampal memory regulation, it is important to
know if the fornix if involved by p-MAPT neuropath-
ology in AD and whether fornix-related imaging bio-
markers might detect sequelae of p-MAPT related
injury versus non-specific changes.
In this study, we sampled and performed p-MAPT
immunohistochemistry on the fornix and efferent and
afferent structures of the hippocampal formation in
39 recently archived brain autopsies. The goal was to
determine whether, and at which NIA/AA stage of
neurofibrillary degeneration, the fornix is involved by
p-MAPT neuropathology in AD. Our cross-sectional
data confirm p-MAPT neuropathology in the fornix
when AD-related neurofibrillary degeneration affects
the hippocampal formation. Furthermore, our results
are compatible with sequential anterograde p-MAPT
neuropathology propagation from the hippocampal
formation to the basal forebrain nuclei via the fornix in
early AD but also suggest the possibility of propagation
of p-MAPT neuropathology into the hippocampal for-
mation via the fornix from the basal forebrain. Our
results are also compatible with the possibility that mo-
dalities to detect p-MAPT neuropathology propagation
or p-MAPT-related axonal injury/loss in the fornix
could potentially provide the basis for novel AD
biomarkers.
Materials and methods
Case selection and tissue harvesting
Adult brain autopsies (118 in total) at Stanford University
School of Medicine from April, 2012 through March,
2014 were examined in this study. To mitigate the
risk of false negative p-MAPT and Aβ staining due to
antigen loss with chronic formalin exposure, tissue
from cases no older than 2 years were stained and
analyzed. Archived hematoxylin and eosin (H&E)
stained autopsy slides were first screened for exclu-
sionary criteria including global hypoxic-ischemic en-
cephalopathy, cerebral edema, temporal lobe infarcts,
demyelination or hemorrhage, primary or metastatic
brain neoplasms, clinical history of seizures, hippo-
campal sclerosis, prion disease, chronic traumatic
encephalopathy, frontotemporal lobar degeneration,
transitional or diffuse Lewy body disease, diffuse cere-
bral infections and hemosiderosis. Archived H&E
stained slides from the remaining brain autopsies of
patients ≥ 65 years of age were next screened for hip-
pocampal neurofibrillary tangles on hematoxylin and
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eosin (H&E)-stained sections. All cases with hippo-
campal neurofibrillary tangles evident on H&E and a
random subset of cases without hippocampal neuro-
fibrillary tangles evident on H&E were selected for
tissue sampling of hippocampal formation efferent
structures. The data include 11 cases from 2011-early
2012, which were analyzed as a pilot cohort in 2013,
and an AD case from mid-2015.
We next examined the archived autopsy brains and
harvested the following tissue sections for analysis of
p-MAPT immunostaining: anterior hippocampus at
the level of the mammillary body; middle frontal and
superior temporal gyri at the level of the mammillary
body; mammillary bodies (bilateral); intraventricular
septum; nucleus accumbens; anterior commissure and
nucleus basalis of Meynert; fornix (coronal sections of
the body); anterior thalamic nucleus. For the body of
the fornix, 2–3 coronal sections from each case were
harvested. Tissue blocks were processed for histology
and embedded in paraffin using routine methods.
Tissue sections (6 μm thickness) were stained with
H&E to confirm that the sampled structures were
indeed represented. In addition to the above sections,
additional tissue blocks from the diagnostic autopsy
evaluations containing the middle frontal gyrus, caud-
ate, putamen, midbrain and cerebellum were also
utilized for the detection of plaques.
Special stains
Sections of the harvested structures underwent anti-
gen retrieval with citrate buffer, were blocked with
Power Block (Biogenex) and stained via immunoper-
oxidase reactions using diaminobenzidine chromo-
genic reactions (Biogenex). The following primary
antibodies were used in the immunoperoxidase reac-
tions: phospho-MAPT (clone AT8; Thermo Scientific,
MN1020, 1:2,000) and amyloid-beta (clone 4G8,
BioLegend, SIG-39220, 1:500). All immunostains for
protein aggregates were run alongside appropriate
positive control cases. Immunoperoxidase stained
slides were counterstained with hematoxylin. For the
modified Bielschowsky stain, slides were deparaffi-
nized, hydrated and incubated in 20 % silver nitrate
for 30 min in a 37° oven. Following rinses in distilled
water, slides were incubated in silver nitrate solution
with ammonium hydroxide for 30 min at 37°, rinsed
and incubated in silver nitrate solution with 1–2
drops of developer solution until the sections turned
black with a golden-brown background. After several
rinses the slides were incubated in 2 % sodium thio-
sulfate, rinsed, dehydrated and coverslipped.
All cases were staged for neurofibrillary degener-
ation according to the Braak staging system using p-
MAPT immunoperoxidase stains of the anterior
hippocampus at the level of the mammillary body, the
middle and superior temporal gyrus at the level of
the mammillary body and the striate and parastriate
cortices [2]. Argyrophillic grain disease was excluded
in all cases on the basis of absence of argyrophillic
grains and coiled oligodendroglial bodies on AT8
immunostains as well as Gallyas silver stains per-
formed on select cases. Cases were staged for Aβ
neuropathology according to the method of Thal and
colleagues [22] in sections of the middle frontal gyrus,
hippocampus, caudate, putamen, nucleus basalis of
Meynert, midbrain and cerebellar cortex. Neocortical
neuritic plaques were scored semi-quantitatively in
sections of the middle temporal gyrus stained via the
modified Bielschowsky method to determine the
Consortium to Establish a Registry for Alzheimer's
Disease (CERAD) neuritic plaque score [11, 12].
Image acquisition and data analysis
Images of p-MAPT staining were acquired with an
Olympus BX51 microscope outfitted with an Olympus
DP73 camera connected to a PC running cellSens Entry
v1.11. White-balanced images of the fields with the
greatest p-MAPT staining were acquired at the following
magnifications: mammillary body (100x); nucleus basalis
of Meynert (100x); nucleus accumbens (100x); Septum
(100x); Alveus (200x); Anterior thalamic nucleus (200x);
Fornix (400x). Images were imported into NIH ImageJ.
The blue channel was extracted and thresholded at the
following cutoff for each structure: fornix 120, septum
120, nucleus accumbens 145, nucleus basalis of Meynert
120, anterior thalamic nucleus 120. A slightly higher
threshold was required in the nucleus accumbens to
filter out nuclear hematoxylin staining in some of the
oligodendroglial cells. Suprathreshold particles were
quantified via the analyze particles function of NIH
ImageJ and events less than 9 square pixels in area were
filtered out of the analysis. Individual p-MAPT stained
events and the total area of suprathreshold pixels as a
fraction of the total image area of 1,918,400 pixels.
Neurons and astrocytes with suprathreshold AT8 stain-
ing were counted manually in the images. Phospho-
MAPT immunoreactivity data in all structures were
compared between NIA/AA stages B0/B1, B2 and B3 of
neurofibrillary degeneration using single factor ANO-
VAs. Post-hoc group comparisons were performed with
Bonferroni tests. Pearson correlation coefficients and
Bonferroni probabilities accounting for multiple compar-
isons were used to correlate basal forebrain tauopathy
with Braak stage of neurofibrillary degeneration, basal
forebrain with AT8-immunoreactive axons in the fornix
and the levels of mammillary body tau astrogliopathy
with patient age. All statistical analyses were performed
with the SYSTAT v.13 statistical software suite.
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Results
A total of 39 cases were included in this study that
satisfied the selection criteria outlined in the Methods.
Demographic and neuropathologic data for these 39
cases are presented in Table 1. The cohort was
comprised of 3 cases with NIA/AA stage B0, 19 with
NIA/AA stage B1, 9 NIA/AA stage B2 and 8 NIA/AA
stage B3 stages of neurofibrillary degeneration accord-
ing to AT8-immunostained sections of 1. the anterior
hippocampus at the level of the mammillary body, 2.
Table 1 Alzheimer disease neuropathologic staging of 39 autopsy cases
Case # Age Gender Amyloid p-MAPT (NIA/AA) p-MAPT (Braak) CERAD NIA-AA Category
1 68 F A0 B0 0 C0 None (possible PART)
2 76 F A1 B0 0 C0 Low
3 65 F A1 B0 0 C0 Low
4 82 M A2 B1 I C1 Low
5 71 M A0 B1 I C0 None (possible PART)
6 67 M A0 B1 I C0 None (possible PART)
7 65 F A0 B1 I C0 None (possible PART)
8 82 F A0 B1 II C0 None (possible PART)
9 75 M A0 B1 II C0 None (possible PART)
10 74 M A0 B1 II C0 None (possible PART)
11 68 F A0 B1 I C0 None (possible PART)
12 83 F A1 B1 II C2 Low
13 84 F A1 B1 II C0 Low
14 87 M A1 B1 II C1 Low
15 75 F A1 B1 II C1 Low
16 79 M A1 B1 II C1 Low
17 77 F A2 B1 II C1 Low
18 73 M A2 B1 II C2 Low
19 76 M A2 B1 II C2 Low
20 76 M A2 B1 II C2 Low
21 68 M A3 B1 II C1 Low
22 71 M A3 B1 II C1 Low
23 83 M A0 B2 III C0 None (possible PART)
24 83 F A1 B2 III C0 Low
25 81 M A1 B2 III C1 Low
26 80 M A2 B2 III C1 Intermediate
27 77 F A2 B2 III C1 Intermediate
28 75 F A2 B2 IV C2 Intermediate
29 84 F A2 B2 IV C2 Intermediate
30 83 M A2 B2 III C2 Intermediate
31 84 F A3 B2 III C2 Intermediate
32 70 F A2 B3 VI C3 Intermediate
33 91 M A3 B3 V C1 Intermediate
34 89 M A3 B3 V C2 High
35 80 F A3 B3 VI C3 High
36 93 F A3 B3 VI C3 High
37 63 M A3 B3 VI C3 High
38 71 M A3 B3 V C3 High
39 85 M A3 B3 V C3 High
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the middle and superior temporal gyri and 3. the para-
striate and striate cortices. Stages B0 and B1 were
combined into a B0-1 group since these stages of
neurofibrillary degeneration exhibit minimal involve-
ment of the hippocampal formation. Eight of our 39
cases (25 %) demonstrated no inferior temporal or mid-
dle frontal Aβ immunoreactive plaques and were com-
prised of 7 cases with stage B1 and 1 case with stage B2
neurofibrillary degeneration, compatible with possible
primary age-related tauopathy (PART) [7]. All other
cases with neocortical tauopathy demonstrated Aβ
plaques and neuritic plaques in line with AD neuro-
pathologic changes. There was no evidence of neocor-
tical astrocytic plaques, tufted astrocytes, argyrophillic
grains, oligodendroglial coiled bodies, Pick bodies or
any other features of non-AD neuronal tauopathy in
any these cases.
In AT8-immunostained sections of the anterior
hippocampus, punctate and wavy AT8 immunoreac-
tive (AT8-ir) processes in the alveus, a major efferent
tract of the hippocampal formation, were conspicuous
in cases with NIA/AA stages B2 and B3, but not in a
case with NIA/AA stage B0-1, neurofibrillary degener-
ation (Fig. 1). We examined AT8 immunoreactivity in
coronal sections of the body of the fornix and discov-
ered small, round, dot-like profiles of AT8-ir axonal
staining only in NIA/AA stages B2 and B3 of neuro-
fibrillary degeneration (Fig. 2a). Image analysis dem-
onstrated that the fornix showed exceedingly rare
AT8-ir puncta in NIA/AA stages B0-1, but demon-
strated frequent AT8-ir puncta in NIA/AA stage B2
(Fig. 2a and c). We observed no further increase in
AT8-ir axon profiles in the fornix in NIA/AA stage
B3 (Fig. 2c). Correlation analysis demonstrated a sig-
nificant correlation between the Braak stage of neuro-
fibrillary degeneration and the density of AT8-ir
axons in the fornix (Fig. 2d).
We next examined AT8 immunoreactivity in pre-
commissural efferent target nuclei of the fornix - the
septum and nucleus accumbens (NA). We detected
Fig. 1 Phospho-MAPT neuropathology is present in the alveus in cases with hippocampal neurofibrillary degeneration. Left panels (original
magnifications 10x): AT8 immunostaining in the hippocampal CA1 sector is demonstrated in representative cases with NIA/AA stages B0-1 (top-left), B2
(middle-left) or B3 (bottom-left) neurofibrillary degeneration. Right panels (original magnifications 200x): A case with B0-1 neurofibrillary degeneration
demonstrated no axonal staining in the alveus (upper-right panel). Cases with B2 and B3 neurofibrillary degeneration (middle-right and lower-right panels,
respectively) demonstrated punctate and wavy axonal AT8 staining in the alveus (arrowheads)
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no significant p-MAPT neuropathology in the septum
in NIA/AA stages B0 and B1 (Fig. 3a and b). How-
ever, in NIA/AA stage B2 and B3, there were signifi-
cant increases in AT8-ir processes and neurons in the
septum (Fig. 3a and b). Correlation analysis demon-
strated a significant correlation between the Braak
stage of neurofibrillary degeneration and the density
of AT8-ir pathology in the septum (Fig. 3c). Only rare
AT8-ir neurons demonstrated granular pre-tangle
staining in the nucleus accumbens(NA) in NIA/AA
stages B0-1 (Fig. 4a and b). AT8-ir processes and neu-
rons were present in the NA in NIA/AA stages B2 and
B3, however they reached statistical significance only in
stage B3 in our cohort (Fig. 4a and b). Correlation analysis
demonstrated a significant correlation between the Braak
stage of neurofibrillary degeneration and the density of
AT8-ir pathology in the NA (Fig. 4c).
In the nucleus basalis of Meynert, magnocellular
neurons with p-MAPT neuropathology in NIA/AA
stages B0 and B1 were rare (Fig. 5a and b) but there
were significant increases in AT8-ir processes and
neurons in NIA/AA stages B2 and B3 (Fig. 5a and b).
Correlation analysis demonstrated strong correlation
between the Braak stage of neurofibrillary degener-
ation and the density of AT8-ir pathology in the
nucleus basalis of Meynert (Fig. 5c).
Sections of the mammillary bodies (MB) were
remarkable for a mix of neuronal and astroglial tauo-
pathy (Fig. 6). In NIA/AA stages B0-1, only very rare
AT8-ir astrocytes and AT8-ir neurons were seen in
the MB (Fig. 6a and b). The density of AT8-ir astro-
cytes, but not AT8-ir neurons, was markedly
increased in the MB in NIA/AA stage B2. The thorn-
shaped morphology of the p-MAPT immunoreactive
astrocytes was consistent with aging-related tau astro-
gliopathy (ARTAG) [9]. In NIA/AA stage B3, there was
a significant increase in AT8-ir neurons as well as
admixed AT8-ir astrocytes in the MB (Fig. 6a and b).
Fig. 2 The body of the fornix demonstrates p-MAPT immunoreactive axons in NIA/AA stages B2 and B3. a. Images (original magnifications 400x)
from coronal sections of the body of the fornix from representative cases with NIA/AA stages B0-1, B2 or B3 neurofibrillary degeneration are shown. Cases
with B0-1 neurofibrillary degeneration demonstrated no punctate axonal staining in the fornix (upper left panel). Cases with B2 and B3 neurofibrillary
degeneration (middle-left and lower-left panels, respectively) demonstrated punctate axonal AT8 staining in the fornix (arrowheads). b. Representative
macroscopic image (original magnification 10x) of and H&E stained section of the body of the fornix. c. Cases with B2 and B3 neurofibrillary degeneration
demonstrated increased AT8-immunoreactive (AT8-ir) axons compared to cases with B0-1 neurofibrillary degeneration (p <0.001, ANOVA; Bonferroni
post-hoc test comparisons as indicated in the figure panel). d. Correlation analysis revealed a significant correlation between Braak stages of neurofibrillary
degeneration and AT8-ir axons in the fornix (n= 39, R= 0.622, p< 0.001)
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Correlation analysis demonstrated no relationship
between the Braak stage of neurofibrillary degeneration
and the density of AT8-ir astrocytes in the MB (Fig. 6c,
top panel) but there was a significant correlation be-
tween the Braak stage of neurofibrillary degeneration
and the density of AT8-ir neurons in the MB (Fig. 6c,
bottom panel). Correlation analysis also demonstrated a
significant correlation between increasing age and in-
creased AT8-ir astrocytes in the MB (n = 37; R = 0.473,
p < 0.004) but there was no significant difference in the
density of AT8-ir astrocytes in the mammillary bodies
between genders (Male: 5 ± 2 AT8-ir astrocytes vs
Female: 2 ± 2 AT8-ir astrocytes; p = 0.285, unpaired
Student’s t test).
AT8 immunostains performed on sections of the
anterior thalamic nucleus (ATN) (Fig. 7) revealed no
significant AT8-ir processes and neurons in the ATN in
NIA/AA stages B0-1 or NIA/AA stage B2 (Fig. 7a and b).
Significant increases in AT8-ir processes and neurons
in the ATN were seen only in NIA/AA stage B3
(Fig. 7a and b). Correlation analysis demonstrated a
significant correlation between the Braak stage of
neurofibrillary degeneration and the density of AT8-ir
pathology in the ATN (Fig. 7c).
We performed correlation analyses to examine the
relationship of AT8-ir axons in the fornix with AT8-
immunoreactivity in the basal forebrain nuclei (Fig. 8).
There was a significant correlation between p-MAPT
neuropathology in the fornix and p-MAPT neuro-
pathology in the nucleus basalis of Meynert (Fig. 8a)
and the septum (Fig. 8b). In the mammillary body,
there was a significant correlation between p-MAPT
neuropathology in the fornix and overall neuronal and
astroglial p-MAPT neuropathology (Fig. 8c), however,
there was no significant correlation with neuronal tauo-
pathy alone (n = 37; R = 0.327, p = 0.288) and only a
trend towards correlation with astroglial tauopathy
alone (n = 37; R = 0.421, p = 0.057) in our cohort. The
correlations between p-MAPT neuropathology in the
fornix and p-MAPT neuropathology in the NA (Fig. 8d)
and in the ATN (Fig. 8e) were not statistically
significant.
Discussion
In this autopsy immunohistology study, we hypothe-
sized that the fornix, a major efferent outflow tract of
the hippocampal formation, is a conduit for the
propagation of p-MAPT neuropathology from the
Fig. 3 The septum demonstrates p-MAPT neuropathology in NIA/AA stages B2 and B3. a. Images (original magnification 100x) from sections of
the septum from representative cases with NIA/AA stages B0-1, B2 or B3 neuropathology are shown. Cases with B0-1 neurofibrillary degeneration
demonstrated no significant process or neuronal staining in the septum (upper panel). Cases with B2 and B3 neurofibrillary degeneration (middle
and lower panels, respectively) demonstrated AT8-ir processes and neurons. b. Cases with B2 and B3 neurofibrillary degeneration demonstrated increased
AT8-ir processes (upper graph; p< 0.001, ANOVA) and neurons (lower graph; p< 0.001, ANOVA) compared to cases with B0-1 neurofibrillary degeneration
(Bonferroni post-hoc test comparisons as indicated in the figure panel). c. Correlation analysis revealed a significant correlation between Braak stages of
neurofibrillary degeneration and both AT8-ir processes (n= 37, R= 0.599, p< 0.001) and AT8-ir neurons (n= 37, R= 0.456, p= 0.015) in the septum
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hippocampus to the basal forebrain in early AD. To
test this hypothesis, we analyzed p-MAPT immuno-
staining in the fornix and its efferent targets in the
basal forebrain in human brain autopsies with early
to advanced AD neuropathologic changes. We ex-
pected that the fornix would recapitulate a core fea-
ture of the Braak and NIA/AA staging systems in the
spread of p-MAPT neuropathology across connected
brain regions with involvement downstream of the
hippocampal formation. Indeed, in cases of B0-1
neurofibrillary degeneration with none or minimal in-
volvement of the hippocampal formation by p-MAPT
neuropathology, we observed no significant p-MAPT
(AT8) immunostaining in the fornix or efferent target
nuclei. In cases of B2 neurofibrillary degeneration, we
observed p-MAPT staining in axonal processes of the
fornix and in precommissural nuclei (septum and nu-
cleus accumbens). The mammillary body, innervated
by postcommissural fibers of the fornix, demonstrated
tauopathy that was predominantly astroglial in stage
B2 and that was mixed neuronal and astroglial in
stage B3. P-MAPT neuropathology was sparse in the
ATN, an efferent target of the fornix and of the
mammillary bodies via the mammillothalamic tract, in
NIA/AA stage B2 but rose significantly in NIA/AA
stage B3. These results of our autopsy study demon-
strate that the fornix is a conduit for p-MAPT neuro-
pathology in AD and are compatible with p-MAPT
neuropathology propagation from the hippocampal
formation to the basal forebrain nuclei via the fornix
as AD-related tauopathy progresses.
Braak and Braak [2–4] described the stereotypical
propagation of p-MAPT neuropathology in AD which
is the basis of the neurofibrillary degeneration staging
system that bears their name. The serial propagation
between synaptically connected regions, like the ento-
rhinal cortex and the hippocampal formation, sup-
ports the hypothesis that axons and synapses play an
important role. Mechanistically, recent work has sup-
ported the concept that MAPT neuropathology is
propagated along connected brain regions and that
the synapse itself is an important factor for, and
perhaps a substrate of, transneuronal p-MAPT neuro-
pathology propagation [5, 6, 8]. Our findings, while
Fig. 4 The nucleus accumbens demonstrates p-MAPT neuropathology in NIA/AA stages B2 and B3. a. Images (original magnification 200x) from
sections of the nucleus accumbens from representative cases with NIA/AA stages B0-1, B2 or B3 neuropathology are shown. Cases with B0-1
neurofibrillary degeneration demonstrated rare AT8-ir process but no significant neuronal staining in the nucleus accumbens (upper panel). Cases
with B2 and B3 neurofibrillary degeneration (middle and lower panels, respectively) demonstrated AT8-ir processes and neurons. b. Cases with B3
neurofibrillary degeneration demonstrated increased AT8-ir processes (upper graph; p < 0.001, ANOVA; Bonferroni post-hoc test comparisons as
indicated) and neurons (lower graph; p < 0.001, ANOVA; Bonferroni post-hoc test comparisons as indicated) compared to cases with B0-1
neurofibrillary degeneration. Cases with B2 neurofibrillary degeneration demonstrated trends towards increased AT8-ir processes and
neurons compared to cases with B0-1 neurofibrillary degeneration (Bonferroni post-hoc test comparisons as indicated in graph panels).
c. Correlation analysis revealed a significant correlation between Braak stages of neurofibrillary degeneration and both AT8-ir processes
(n = 37, R = 0.656, p < 0.001) and AT8-ir neurons (n = 37, R = 0.532, p = 0.002) in the nucleus accumbens
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generally not surprising in the context of these lines
of evidence, are important because they fill a gap in
our knowledge of p-MAPT propagation in structures
not routinely sampled in AD neuropathologic
examinations.
Since cognitive impairment in AD is correlated with
the spread of pathologic tau [14, 16], it is possible
that the risk of progression from MCI to AD might
be predicted by the spread of p-MAPT from the
hippocampus via the fornix. Consistent with this
premise, elevated CSF MAPT and p-MAPT have
become important biomarkers in the clinical diagnosis
of AD [19]. Diffusion tensor imaging MRI studies
have suggested that increased diffusion measures in
the fornix may predict progression in AD and are
suggested to relate to p-MAPT related axonal injury
[1, 18], however, definitive pathologic correlation is
lacking. Ongoing work in in vivo MAPT imaging [20]
might also facilitate detection of p-MAPT propagation
in the fornix.
We performed correlation analyses of p-MAPT
staining in the fornix and basal forebrain nuclei to
further probe the tauopathy patterns in these inter-
connected structures. The density of p-MAPT staining
in the fornix and all the basal forebrain structures
demonstrated significant correlation with the Braak
stage of neurofibrillary degeneration, compatible with
the progressive spread of tauopathy to these struc-
tures as AD neurofibrillary degeneration advances
along the regional pattern described by Braak and
Braak [2–4]. Interestingly, correlation analysis of the
density of fornix tauopathy and the density of tauopa-
thy in basal forebrain structures was not uniform.
The strongest correlation between tauopathy in the
fornix and nucleus basalis of Meynert suggests the
possibility that nucleus basalis projections to the
hippocampus through the fornix contribute to fornix
tauopathy in addition to efferent hippocampal forma-
tion projections. Tauopathy in the fornix was also
significantly correlated with tauopathy in the septum
but was not significantly correlated with tauopathy in
the NA or ATN. In our cohort, there were cases with
relatively higher levels of tauopathy in the NA and
ATN but lower levels of fornix p-MAPT that
Fig. 5 The nucleus basalis of Meynert demonstrates p-MAPT neuropathology in NIA/AA stages B2 and B3. a. Images (original magnification 100x)
from sections of the nucleus basalis of Meynert from representative cases with NIA/AA stages B0-1, B2 or B3 neuropathology are shown. Cases
with B0-1 neurofibrillary degeneration demonstrated no significant process or magnocellular neuronal staining in the nucleus basalis (top panel).
Cases with B2 and B3 neurofibrillary degeneration (middle and bottom panels, respectively) demonstrated AT8-ir processes and neurons. b. Cases
with B3 neurofibrillary degeneration demonstrated increased AT8-ir processes (upper graph; p< 0.001, ANOVA; Bonferroni post-hoc test comparisons as
indicated) and neurons (lower graph; p< 0.001, ANOVA; Bonferroni post-hoc test comparisons as indicated) compared to cases with B0-1 neurofibrillary
degeneration. Cases with B2 neurofibrillary degeneration demonstrated increased AT8-ir neurons and a strong trend towards increased AT8-ir processes
compared to cases with B0-1 neurofibrillary degeneration (Bonferroni post-hoc test comparisons as indicated in graph panels). c. Correlation analysis
revealed a significant correlation between Braak stages of neurofibrillary degeneration and both AT8-ir processes (n= 30, R= 0.802, p< 0.001) and AT8-ir
neurons (n= 30, R = 0.836, p< 0.001) in the nucleus basalis of Meynert
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contributed to this lack of correlation. Since these
cases represent NIA/AA staged B2 and B3, lack of
concordance might be due to spread of p-MAPT
neuropathology to the basal forebrain via other path-
ways, for example via the amygdala in the case of the
NA, or could reflect decreases in fornix p-MAPT-
positive axons due to axonal loss.
Our autopsy study also highlighted two additional
tauopathies that can involve the mesiotemporal lobe
and basal forebrain: PART [7] and ARTAG [10].
PART is characterized by neurofibrillary degeneration
in a pattern resembling AD but in the absence of sig-
nificant Aβ neuropathology. Since we performed Aβ
immunostains only on the middle and inferior tem-
poral gyri and are unable to completely exclude the
possibility of amyloid plaques in other neocortical
regions, we categorized patients lacking amyloid pla-
ques as possible PART. Seven brains in our study
demonstrated possible PART confined to the entorhi-
nal cortex with sparse involvement of the CA1 sector
of the hippocampus (Braak stage I-II). Overall, p-
MAPT staining was sparse in the fornix in cases with
entorhinal neurofibrillary degeneration and there was
no significant difference in fornix p-MAPT axonal
staining between the 12 brains with B1 Alzheimer
disease neuropathologic changes (8.7 ± 2.6 p-MAPT-
positive axonal profiles) and the seven brains with
possible Braak stage I-II PART (5.7 ± 2.2 p-MAPT-
positive axonal profiles). Only one brain in our
autopsy series demonstrated possible Braak stage III
PART and it showed approximately ½ of the mean
axonal p-MAPT staining for the B2 neurofibrillary
degeneration group. These results suggest that fornix
p-MAPT neuropathology can be seen in Braak stage ≥
III PART. Since dementia is uncommon in patients
with PART [7], the finding of p-MAPT-related axonal
damage in the fornix highlights the potential import-
ance of in vivo Aβ imaging and biomarkers to differ-
entiate patients with AD who are more likely to
progress to dementia.
Additionally, several brains demonstrated abundant
p-MAPT immunoreactive thorn-shaped astrocytes in
the MB. We suspect that this finding is most likely
related to ARTAG [10] as it was seen in all NIA/AA
stages of neurofibrillary degeneration and its density
correlated with patient age. However it is interesting
Fig. 6 The mammillary bodies demonstrated AT8-ir astrocytes most prominently in NIA/AA stage B2 and AT8-ir neurons in NIA/AA stage B3.
a. Images (original magnification 200x) from sections of the mammillary bodies from representative cases with NIA/AA stages B0-1, B2 or B3
neuropathology are shown. Cases with B0-1 neurofibrillary degeneration demonstrated no significant neuronal AT8 staining in the nucleus
basalis (upper panel). Cases with B2 neurofibrillary degeneration (middle panel) demonstrated predominantly AT8-ir astrocytes whereas cases
with B3 neurofibrillary degeneration (lower panel) demonstrated predominantly AT8-ir neurons. b. Cases with B2 neurofibrillary degeneration
demonstrated increased AT8-ir astrocytes (upper graph; p < 0.004, ANOVA; Bonferroni post-hoc test comparisons as indicated) but no significant
increase in AT8-ir neurons. Cases with B3 neurofibrillary degeneration demonstrated increased AT8-ir neurons compared to B0-1 and B2 (lower graph;
p < 0.001, ANOVA; Bonferroni post-hoc test comparisons as indicated). c. Correlation analysis revealed a significant correlation between Braak stages of
neurofibrillary degeneration and AT8-ir neurons (n = 37, R = 0.628, p < 0.001). There was no significant correlation between Braak stage and AT8-ir
astrocytes (n = 37, R = 0.188, p = 1) in the mammillary bodies
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to note that MB tau astrogliopathy was most promin-
ent in NIA/AA stage B2 of neurofibrillary degener-
ation and preceded neuronal tau pathology in the MB
in our autopsy cohort. Furthermore, there was a mod-
est but statistically significant correlation between the
combination of astroglial and neuronal tauopathy in
the MB and tauopathy in the fornix. Although we
favor these findings to represent ARTAG, they could
indicate a role for tau astrogliopathy in tau propaga-
tion from the fornix to the mammillary body. Further
studied are needed to address the significance of tau
astrogliopathy in the MB.
The major limitations of our study are its cross-
sectional design and its small sample size. We have
inferred from the cross-sectional design of this
autopsy study that the fornix propagates p-MAPT
neuropathology from the hippocampus to efferent
structures in the medial basal forebrain. However, in
vivo tau imaging, DTI and post-mortem neuropatho-
logic correlation in patients with neuropsychiatric
evaluations will be needed to determine if this is the
true progression sequence of AD-related tau path-
ology from the hippocampus and its significance with
respect to the risk of progression from MCI to de-
mentia. Out of concern for the possible impairment
of antigen immunostaining with chronic formalin-
fixation, we limited our study to archived autopsies
no older than 2 years. Furthermore, as p-MAPT
neuropathology can be associated with diverse brain
diseases, we eliminated cases with brain pathologies
that might affect the pattern of p-MAPT neuropathol-
ogy or that might affect our immunohistochemical
detection of p-MAPT neuropathology. Despite the re-
sultant small sample size or our study, our data ro-
bustly demonstrate that axonal AT8 immunoreactivity
in the fornix is present in the limbic stage of AD
neuropathology and does not precede hippocampal
involvement. It is possible that tau antibodies that de-
tect earlier phosphorylation states or oligomeric tau
could render additional insights into tau propagation
among the medial temporal lobe and basal forebrain.
Nonetheless, our findings largely support the expected
model of AD-related p-MAPT neuropathology propa-
gation from the hippocampus to the basal forebrain
via the fornix in NIA/AA stages B2 and B3 of neuro-
fibrillary degeneration. However, our findings are
Fig. 7 The anterior thalamic nucleus demonstrates p-MAPT neuropathology predominantly in NIA/AA stage B3. a. Images (original magnification 200x)
from sections of the anterior thalamic nucleus from representative cases with NIA/AA stages B0-1, B2 or B3 neuropathology are shown.
Cases with B0-1 neurofibrillary degeneration demonstrated no significant process or neuronal staining in the anterior thalamic nucleus (upper panel). Cases
with B2 neurofibrillary degeneration (middle panel) demonstrated only very rare AT8-ir processes and neurons. Cases with B3 neurofibrillary degeneration
(bottom panel) demonstrated frequent AT8-ir processes and neurons. b. Cases with B3 neurofibrillary degeneration, but not B2 neurofibrillary degeneration,
demonstrated increased AT8-ir processes (upper graph; p < 0.001, ANOVA; Bonferroni post-hoc test comparisons as indicated) and neurons
(lower graph; p< 0.001, ANOVA; Bonferroni post-hoc test comparisons as indicated) compared to cases with B0-1 neurofibrillary degeneration. c. Correlation
analysis revealed a significant correlation between Braak stages of neurofibrillary degeneration and both AT8-ir processes (n= 37, R= 0.689, p< 0.001) and
AT8-ir neurons (n= 37, R= 0.767, p< 0.001) in the anterior thalamic nucleus
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compatible with the possibilities that the fornix car-
ries p-MAPT to the hippocampal formation from the
nucleus basalis of Meynert and that basal forebrain
nuclei may propagate p-MAPT neuropathology from
structures other than the fornix.
Conclusions
In conclusion, as radiologic modalities that detect
MAPT neuropathology and MAPT-related axonal dam-
age continue to show promise for the in vivo diagnosis
and prognostication for patients with early AD, it is
critical that we have a full understanding of MAPT
neuropathology propagation patterns in the aging hu-
man brain. Our study confirms that the fornix demon-
strates p-MAPT neuropathology in NIA/AA stages B2
and B3 of neurofibrillary degeneration and suggests
that the fornix propagates p-MAPT neuropathology
from the hippocampal formation to the basal forebrain
as AD progresses. Additional work is necessary to fur-
ther understand p-MAPT neuropathology propagation
in these interconnected structures and to correlate MRI
changes and cognitive data with p-MAPT neuropathol-
ogy in these structures in AD.
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